Dose Response Demonstrated Across Efficacy EndpointsResearchers evaluated the efficacy and safety of delgocitinib cream in 251 adults with mild to severe atopic dermatitis. Participants were randomly assigned in a 1:1:1:1:1 ratio to receive delgocitinib cream at concentrations of 1 mg/g, 3 mg/g, 8 mg/g, or 20 mg/g, or a cream vehicle. Compared with the cream vehicle, all delgocitinib cream doses produced significantly greater reductions in Eczema Area and Severity Index scores. The proportion of patients achieving Validated Investigator’s Global Assessment for Atopic Dermatitis treatment success increased with higher delgocitinib cream concentrations. Adverse events occurred in 44.5% of patients receiving delgocitinib cream and 56.0% of those receiving the cream vehicle.